A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes
Clinical trial NCT06712680 · RECRUITING
Trial details
- NCT number
- NCT06712680
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-27
- Primary completion
- 2028-04-10
- Enrollment
- 115
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.